Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Top Story

FDA approves Abraxane for NSCLC

October 13, 2012 1:14 AM UTC

FDA approved an sNDA from Celgene Corp. (NASDAQ:CELG) for Abraxane nab-paclitaxel for first-line treatment of advanced non-small cell lung cancer (NSCLC). The albumin stabilized nanoparticle formulati...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article